EZH2蛋白在前列腺癌中的表达

Expression of EZH2 in prostate cancer and its clinicopathologic significance

目的探讨EZH2在前列腺癌中的表达及意义。方法应用免疫组化方法检测EZH2和PTEN在62例前列腺癌和30例良性前列腺增生症中的表达状况。结果 EZH2在前列腺癌及前列腺增生症中的阳性率分别为88.7%、66.7%,两组中的差异有统计学意义(P<0.05)。EZH2与患者的术前PSA水平、年龄、临床分期及Gleason分级均无相关性。前列腺癌中EZH2和PTEN的表达明显呈负相关(rs=-0.368,P<0.01)。结论 EZH2可能与前列腺癌的发生发展相关,并抑制PTEN基因的表达,共同参与前列腺癌的发生。

Objective To investigate the expression of EZH2 protein in prostate cancers and its clinicopathologic significance.Methods The expression of EZH2 and PTEN were assessed by immunohistochemistry in 62 cases of prostate cancer and 30 cases of beneign prostatic hyperplasia.Results The positive rates of EZH2 in prostate cancers and beneign prostatic hyperplasias were 88.7%,66.7% respectively,which difference had statistical significance（P〈0.05）.There was notable negative correlation of staining of prostate carcinomas between EZH2 and PTEN（rs=-0.368,P〈0.01）.There was no significant correlation of carcinomas for EZH2 expression with preoperative serum PSA level,patient age,Gleason grading,clinical stage（P〈0.05）.Conclusion EZH2 may be involved in the formation of prostate cancers and suppress the expression of PTEN,collaborate to promote the occurrence of cancer.